RBC keeps its Sell rating and AUD 3.60 target for Atlas Arteria stock

Published on 10/20/2026 at 20:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half net income reached AUD 116.40 million, up 8.60 percent from 2025 results. Atlas Arteria stock costs EUR 2.31 on October 20, 2026.

Analyst target and results

RBC Capital maintained its Sell rating and set a target of AUD 3.60 on September 30, 2026.
First-half 2026 net income reached AUD 116.40 million, up 8.60 percent from the prior-year period.
Atlas Arteria stock costs EUR 2.31 at Lang & Schwarz on October 20, 2026 at 8:03 p.m. CEST.

Atlas Arteria, AU0000013559, Illustration mit AI erstellt.

Atlas Arteria (ISIN AU0000013559) is facing a cautious analyst view after RBC Capital maintained its Sell rating and set an AUD 3.60 price target on September 30, 2026, as The Globe and Mail reported. Atlas Arteria stock was trading at EUR 2.31 at Lang & Schwarz on October 20, 2026 at 8:03 p.m. CEST.

RBC target stays below the market

RBC's AUD 3.60 target sits 2.17 percent below the AUD 3.68 ASX price used in the September 30 analyst assessment. The same report cited an analyst consensus of Hold with an AUD 4.68 average target, putting RBC's view below the broader consensus.

The target distance matters because Atlas Arteria's latest reported earnings combined higher profit with lower revenue. Simply Wall St reported first-half 2026 revenue of AUD 74.30 million, down 4.10 percent from the prior-year period, while net income rose 8.60 percent to AUD 116.40 million. Earnings per share reached AUD 0.08, compared with AUD 0.074 in the first half of 2025.

Stock position and valuation

Atlas Arteria closed its ASX session at AUD 3.68 on October 20, 2026, down 1.60 percent on the day. The 52-week range was AUD 3.66 to AUD 5.24, leaving the stock AUD 0.02 above its low and AUD 1.56 below its high. Market capitalization stood at AUD 5.3 billion, while the trailing price-to-earnings ratio was 20.42.

What the peer figures show

Atlas Arteria operates toll-road assets through a stapled security listed on the Australian Securities Exchange. Its sector profile is smaller than Transurban, which had a market capitalization of AUD 42.6 billion and a price-to-earnings ratio of 116.09 on October 20, 2026. Vinci traded on Euronext Paris with a market capitalization of EUR 59.3 billion and a price-to-earnings ratio of 11.82.

The company says its portfolio includes APRR, ADELAC, Dulles Greenway and Warnow Tunnel, while its distribution policy targets a payout range of 90 to 110 percent of free cash flow, according to Atlas Arteria. The combination of recurring toll-road assets and distribution commitments remains central to how the stock is assessed.

Price and analyst view

RBC's AUD 3.60 target contrasts with the AUD 4.68 consensus target cited on September 30, 2026. The next investor reference point is the company's upcoming reporting cycle, while the latest half-year figures already show the tension between rising net income and declining revenue.

Atlas Arteria stock was trading at EUR 2.31 at Lang & Schwarz on October 20, 2026 at 8:03 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Atlas Arteria stock.